$BAVA (-1.93%) The German-Danish vaccine specialist Bavarian Nordic clearly exceeded market expectations with its figures for the second quarter. The company easily exceeded estimates for both turnover and profit. Bavarian Nordic then also specified its forecast for the current year.
With sales of 1.43 billion Danish kroner (equivalent to 191.2 million euros) in the second quarter, the vaccine manufacturer clearly beat the estimate of 1.18 billion kroner. EBITDA amounted to 420 million kroner (56.3 million euros); analysts had only estimated just under 203 million kroner.
Bavarian Nordic now expects sales of around 5.30 billion kronor and EBITDA of 1.35 billion kronor for 2024. Both figures are at the upper end of the previously defined target range.
Bavarian Nordic $BAVA (-1.93%) has received an order for 440.000 doses of its vaccine against Mpox and smallpox from a European 🇪🇺 state, which will 2024 will be delivered in 2024.
By the end of next year, the company can deliver up to ten million doses, of which two million before the end of this year.
The production of the vaccine is already being ramped up before ramped up.
Bavarian Nordic and BioNTech are two interesting companies in the field of Mpox vaccines. Bavarian Nordic offers the only licensed vaccine (MVA-BN) and is expanding globally to meet the growing demand. BioNTech, on the other hand, is developing an mRNA vaccine that could ensure flexible and rapid production thanks to its technology. $BAVA (-1.93%) $BNTX (-2.25%)
Bavarian Nordic has proven products, while BioNTech could convince through innovation. Both companies offer a lot of potential, but which approach is more successful in the long term? What do you think?
Bavarian Nordic $BAVA (-1.93%) plans to expand the production of its Mpox (monkeypox)-vaccine by the end of 2025 to ten million doses, with two million doses should already be available this year.
The WHO 🌎 has Mpox as a global health emergency.
Since January 2023, the Democratic Republic of Congo 🇨🇩 around 27,000 cases and over 1,100 deaths have been reported.
In Sweden 🇸🇪, the first case of a new Mpox variant outside Africa was recently confirmed.
Just filled up the 1000 shares of this small company in my portfolio! I expect the sale of Mpox vaccinations to result in significantly higher profits.
The declaration of a global health emergency due to the Mpox virus by the World Health Organization (WHO) gave Bavarian Nordic a boost. The shares of the Danish biotechnology company rose by up to 17 percent and reached 261 kroner, the highest level in almost two years. Bavarian Nordic produces a vaccine against Mpox and announced on Tuesday that the EU agency for crisis preparedness and response HERA had placed an order for vaccine doses to be delivered to Africa. The company also received 156.8 million dollars from the US government to expand its vaccine production.
